{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:23:37Z","timestamp":1793931817435,"version":"4.8.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The majority of patients with refractory, advanced-stage mycosis fungoides (MF) or S\u00e9zary syndrome (SS) have a life expectancy of &amp;lt;5 years. Here, we report a phase 2 study of a novel nonmyeloablative allogeneic transplantation strategy tailored for this patient population. This study has completed the enrollment, and 35 patients (13 MF, 22 SS) have undergone transplant as planned. The majority (80%) of the patients had stage IV disease and received multiple previous systemic therapies. All patients had active disease at the time of conditioning using total skin electron beam therapy, total lymphoid irradiation, and antithymocyte globulin, and received allograft infusion as outpatients. Cyclosporine or tacrolimus and mycophenolate mofetil were used for graft-versus-host disease (GVHD) prophylaxis. Patients tolerated the transplant well, with 1- and 2-year nonrelapse mortality of 3% and 14%, respectively. The day +180 cumulative incidence of grade 2 to 4 acute GVHD was 16%, and the 2-year incidence of moderate\/severe chronic GVHD was 32%. With a median posttransplant follow-up of 5.4 years, the 2-, 3-, and 5-year overall survival rates were 68%, 62%, and 56%. Using high-throughput sequencing of the T-cell receptor for minimal residual disease monitoring, we observed that 43% achieved molecular remission, which was associated with a lower incidence of disease progression or relapse (9% vs 87%; P = .02). Our study also showed that patients who were aged \u226565 years at the time of allotransplant had similar clinical outcomes compared with younger patients. Thus, we have developed an alternative and potentially curative nonmyeloablative allogeneic transplant regimen for patients with advanced stage MF\/SS. This trial was registered at www.clinicaltrials.gov as #NCT00896493.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001627","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T17:05:56Z","timestamp":1600362356000},"page":"4474-4482","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":49,"title":["Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma"],"prefix":"10.1182","volume":"4","author":[{"given":"Wen-Kai","family":"Weng","sequence":"first","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"},{"name":"Department of Dermatology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1993-4172","authenticated-orcid":false,"given":"Sally","family":"Arai","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Rezvani","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Johnston","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lowsky","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-4305","authenticated-orcid":false,"given":"David","family":"Miklos","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Shizuru","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-6136","authenticated-orcid":false,"given":"Lori","family":"Muffly","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everett","family":"Meyer","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Negrin","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Almazan","sequence":"additional","affiliation":[{"name":"Department of Dermatology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5931-4915","authenticated-orcid":false,"given":"Lynn","family":"Million","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9061-7351","authenticated-orcid":false,"given":"Michael","family":"Khodadoust","sequence":"additional","affiliation":[{"name":"Department of Dermatology,"},{"name":"Division of Medical Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Hoppe","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn H.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology,"},{"name":"Division of Medical Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,9,17]]},"reference":[{"issue":"5","key":"2020092112284345100_B1","doi-asserted-by":"crossref","first-page":"522","DOI":"10.6004\/jnccn.2020.0022","article-title":"NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020\u2014featured updates to the NCCN Guidelines","volume":"18","author":"Mehta-Shah","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"2020092112284345100_B2","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2020092112284345100_B3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2008.0033","article-title":"Review of the treatment of mycosis fungoides and S\u00e9zary syndrome: a stage-based approach","volume":"6","author":"Horwitz","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"issue":"21","key":"2020092112284345100_B4","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"32","key":"2020092112284345100_B5","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"issue":"29","key":"2020092112284345100_B6","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"issue":"18","key":"2020092112284345100_B7","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","article-title":"Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"119","author":"Horwitz","year":"2012","journal-title":"Blood"},{"issue":"32","key":"2020092112284345100_B8","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"issue":"32","key":"2020092112284345100_B9","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020092112284345100_B10","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"2020092112284345100_B11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Specht","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2020092112284345100_B12","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0889-8588(18)30058-3","article-title":"Electron beam treatment for cutaneous T-cell lymphoma","volume":"9","author":"Jones","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"2020092112284345100_B13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jaad.2014.10.014","article-title":"Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials","volume":"72","author":"Hoppe","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"2020092112284345100_B14","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"issue":"18","key":"2020092112284345100_B15","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009","volume":"18","author":"Talpur","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2020092112284345100_B16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: a comparative study of systemic therapy","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2020092112284345100_B17","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.bbmt.2009.04.017","article-title":"A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and S\u00e9zary syndrome","volume":"15","author":"Wu","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"2020092112284345100_B18","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","article-title":"Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome","volume":"28","author":"Duvic","year":"2010","journal-title":"J Clin Oncol"},{"issue":"29","key":"2020092112284345100_B19","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","article-title":"Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Duarte","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020092112284345100_B20","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/bmt.2011.201","article-title":"Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas","volume":"47","author":"Paralkar","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020092112284345100_B21","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3324\/haematol.2013.098145","article-title":"Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas","volume":"99","author":"de Masson","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"2020092112284345100_B22","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/annonc\/mdv473","article-title":"Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution","volume":"26","author":"Hosing","year":"2015","journal-title":"Ann Oncol"},{"issue":"11","key":"2020092112284345100_B23","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/bmt.2014.161","article-title":"Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome","volume":"49","author":"Lechowicz","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2020092112284345100_B24","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1001\/archdermatol.2010.200","article-title":"Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression","volume":"146","author":"Samimi","year":"2010","journal-title":"Arch Dermatol"},{"issue":"4","key":"2020092112284345100_B25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1396-0296.2003.01647.x","article-title":"Mycosis fungoides: radiation therapy","volume":"16","author":"Hoppe","year":"2003","journal-title":"Dermatol Ther"},{"issue":"13","key":"2020092112284345100_B26","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa050642","article-title":"Protective conditioning for acute graft-versus-host disease","volume":"353","author":"Lowsky","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"2020092112284345100_B27","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1182\/blood-2009-03-211441","article-title":"TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors","volume":"114","author":"Kohrt","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2020092112284345100_B28","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/00007890-200205150-00005","article-title":"Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation","volume":"73","author":"Millan","year":"2002","journal-title":"Transplantation"},{"issue":"10","key":"2020092112284345100_B29","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1038\/sj.leu.2404335","article-title":"Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning","volume":"20","author":"Baron","year":"2006","journal-title":"Leukemia"},{"issue":"214","key":"2020092112284345100_B30","doi-asserted-by":"crossref","first-page":"214ra171","DOI":"10.1126\/scitranslmed.3007420","article-title":"Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma","volume":"5","author":"Weng","year":"2013","journal-title":"Sci Transl Med"},{"issue":"19","key":"2020092112284345100_B31","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2009-04-217604","article-title":"Comprehensive assessment of T-cell receptor \u03b2-chain diversity in alphabeta T cells","volume":"114","author":"Robins","year":"2009","journal-title":"Blood"},{"issue":"18","key":"2020092112284345100_B32","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020092112284345100_B33","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020092112284345100_B34","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"32","key":"2020092112284345100_B35","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020092112284345100_B36","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nm1038","article-title":"Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease [published correction appears in Nat Med. 2004;10(6):649]","volume":"10","author":"Merad","year":"2004","journal-title":"Nat Med"},{"issue":"6","key":"2020092112284345100_B37","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.bbmt.2014.02.023","article-title":"Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms","volume":"20","author":"Benjamin","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020092112284345100_B38","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"issue":"11","key":"2020092112284345100_B39","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3324\/haematol.2014.105981","article-title":"Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies","volume":"99","author":"Oudin","year":"2014","journal-title":"Haematologica"},{"issue":"27","key":"2020092112284345100_B40","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2008.20.9692","article-title":"Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia","volume":"27","author":"Ringd\u00e9n","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020092112284345100_B41","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1097\/01.TP.0000129809.09718.7E","article-title":"A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation","volume":"78","author":"Le Blanc","year":"2004","journal-title":"Transplantation"},{"issue":"4","key":"2020092112284345100_B42","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.bbmt.2013.01.016","article-title":"Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies","volume":"19","author":"Gladstone","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2020092112284345100_B43","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/leu.2013.52","article-title":"Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia","volume":"27","author":"Logan","year":"2013","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/18\/4474\/1758764\/advancesadv2020001627.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/18\/4474\/1758764\/advancesadv2020001627.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T16:32:03Z","timestamp":1600705923000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/18\/4474\/463767\/Nonmyeloablative-allogeneic-transplantation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,17]]},"references-count":43,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2020,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001627","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,17]]}}}